Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Gland and Hormone Related Diseases

Nervous System Diseases

Symptoms and General Pathology

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Blood and Lymph Conditions

Mouth and Tooth Diseases

Rare Diseases

Uterine Cervical Neoplasms

Carcinoma

Cholangiocarcinoma

Breast Neoplasms

Pancreatic Neoplasms

Melanoma

Prostatic Neoplasms

Stomach Neoplasms

Glioblastoma

Brain Neoplasms

Astrocytoma

Anorexia

Vomiting

Head and Neck Neoplasms

Sarcoma

Carcinoma, Renal Cell

Neoplasm Metastasis

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Urinary Bladder Neoplasms

Headache

Liver Neoplasms

Seizures

Sleepiness

Mesothelioma

Mesothelioma, Malignant

Mitral Valve Insufficiency

Kidney Neoplasms

Esophageal Neoplasms

Thymoma

Thymus Neoplasms

Tongue Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Male Urogenital Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neoplastic Processes

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urologic Diseases

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Adenoma

Neoplasms, Mesothelial

Thoracic Neoplasms

Glioma

Neoplasms, Neuroepithelial

Esophageal Diseases

Lymphatic Diseases

Mouth Neoplasms

Mouth Diseases

Stomatognathic Diseases

Tongue Diseases

Esophageal Cancer

Pancreatic Cancer

Ovarian Cancer

Bile Duct Cancer

Renal Cell Carcinoma

Stomach Cancer

Ovarian Epithelial Cancer

Soft Tissue Sarcoma

Malignant Mesothelioma

Tongue Cancer

Neuroepithelioma

Oral Cancer

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Temozolomide

Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.

QBS10072S targets cancers with high LAT1 expression.

QBS10072S

This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma.

The dose escalation scheme for this trial employs an mTPI-2 design.

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma

MTD will be determined by presence of AEs as characterized by type, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.

Safety and tolerability will be determined by adverse events as characterized by type, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.

Determine the maximum plasma concentration of QBS10072S.

Determine the plasma concentration of QBS10072S over time.

Determine the half life of QBS10072S in plasma; the half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value.

Determine the time it takes to achieve maximum concentration of QBS10072S in plasma.

Novotech (Australia) Pty Limited

Quadriga Biosciences, Inc.

Infections

Recurrence

Adenoviridae Infections

Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.

DNX-2401

Tumor Removal

Frederick F. Lang, MD, BS

The goal of this clinical research study is to find the highest tolerable dose of DNX-2401 that can be injected directly into brain tumors and into the surrounding brain tissue where tumor cells can multiply. A second goal is to study how the new drug DNX-2401 affects brain tumor cells and the body in general.

The Study Drug:

DNX-2401 (formerly known as Delta-24-RGD-4C) is a virus that works by killing brain tumor cells. It is made from a common cold virus, called adenovirus, type 5. This virus normally causes the common cold, and most people around the world have been exposed many times to this common, naturally-occurring virus during their lives. Two (2) changes have been made to the adenovirus to make DNX-2401. The first change was to make the virus only grow in cancer cells. The second change was made to allow DNX-2401 to enter cancer cells more easily. These changes make DNX-2401 more able to multiply and kill cancer cells and less likely to multiply in normal cells.

Study Groups:

Participants will eventually be divided into 2 groups (Groups A and B).

At first, all participants will only be enrolled into Group A. Participants in Group A will receive the study drug but will not have the recurrent malignant glioma tumor removed by surgery.

Enrollment into Group B will not start until the FDA has reviewed initial results on how the treatment for participants in Group A effected brain tumor cells and the body in general. Once approval for enrollment is given, all eligible participants will be assigned to Group B and will receive the study drug and have their tumors removed by surgery. If you are to receive surgery, you will be asked to sign a separate surgical consent form to help further explain the operation.

If you are found to be eligible to take part in this study, you will be assigned to a dose level of DNX-2401 based on when you joined this study. Up 8 dose levels of DNX-2401 will be tested. Three (3) participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of DNX-2401 is found. You will be informed of which dose you will receive.

Study Drug Administration:

DNX-2401 is given by a surgical procedure where a neurosurgeon precisely injects DNX-2401 through a catheter (small tube) that is inserted into your brain tumor. You will stay in the hospital and be watched closely afterward for up to 48 hours, but it may be longer if your doctors feel that you are not ready to go home.

After receiving DNX-2401, all participants must wear a mask. You must also stay away from pregnant women, babies, children under three years of age, elderly people and large groups of people who may have weaker defenses to disease or those who can spread a disease. You must also stay away from other patients who may have immune system problems, such as people with AIDS, or people who are getting chemotherapy or radiation therapy. The study doctors will decide how long you will need to follow these precautions. You should not donate blood or sperm for at least 6 months after receiving DNX-2401.

Group A:

Before receiving DNX-2401, participants in Group A will have a sample (stereotactic biopsy) of brain tumor tissue collected to confirm that recurrent malignant glioma is present. On the morning of the biopsy, you will have an MRI (with dye). A metal frame will be placed on your head and an MRI of your brain will be done. Before the MRI, a dye will be injected to help give the doctors a better picture of your brain. The head frame allows the surgeon to use MRI to identify the precise location of the tumor within the brain. The frame will stay in place for several hours while the procedure is being performed.

A portion of your head will be shaved for the biopsy. You will have a small incision (cut) in your head (about 2-3 inches). The protective covering of the brain (dura) will be opened and a piece of brain tumor will be removed. If, under a microscope, the biopsy shows that the tumor is still malignant glioma, you will then have an injection of DNX-2401. The anesthesiologists (doctor who gives the anesthesia) may give you medication to make you sedated (anesthesia). They will place a needle into your vein (intravenous line or "IV") to give you this medicine. The anesthesia is given so that you do not feel any pain or discomfort and do not move during the MRI or the surgery.

A small catheter will be placed into the tumor and the metal frame will help guide the proper placement. Some anti-inflammatory medication (a steroid called dexamethasone) will be given in your vein. Then DNX-2401 will be slowly injected into the tumor over about 10 minutes. After the injection, the incision will be closed in a standard and cosmetically acceptable manner.

Group B:

Before receiving DNX-2401, participants in Group B will have a biopsy to confirm that the tumor is recurrent glioma. The procedure will be exactly the same as described for those in Group A. This is called "Stage 1." However, at the end of the biopsy and study drug injection procedure, the catheter will be clipped off next to your skull and a portion of the tube will remain inside the tumor and in place for the next 2 weeks. The scalp will be closed over the clipped catheter to prevent any possibility of infection. The next day, you will have a CT scan to check the tumor and placement of the catheter.

Group A Follow-up Visits:

You will come back to the study center for check-ups at 4, 7,14 and 28 days, then 2, 3, and 4 months after the injections, and then every 2 months for 2 years. After that, you will be asked to return to the clinic every 4 months for the rest of your life. At each visit, the following tests and procedures will be performed:

* You will be asked to give information about any new medications and therapies, including vitamins, herbs, and supplements that you may be taking.
* You will be asked to describe any changes in your health or how you feel.
* You will have a neurological exam.
* Your weight will be measured on Day 28 and at 2, 3 and 4 months.
* Your vital signs will be measured.
* You will be asked to provide a blood sample (about 1 teaspoon), a urine sample and a swab of your nose and throat will be taken.
* You will have blood tests (about 4 teaspoons) to evaluate your clinical status on Days 4, 7, 28, and at 2, 3 and 4 months.
* Blood (about 2 teaspoons) will be collected to look for the presence of anti-AD5 and virus.
* Women who are able to become pregnant must have a blood (about 1 teaspoon) pregnancy test on 1 and 4 month visit and all follow-up visits after that.
* You will have an MRI at each visit except for Day 4.
* After the 4 month visit, you will have an evaluation to see how you have responded to treatment for the first 2 years and every 4 months after that.

Group B Follow-up Visits:

You will be seen in the study center for check-ups on Days 4, 7, and 13 after the injection but before your craniotomy. At each visit the following tests and procedures will be performed:

* You will be asked to give information about any new medications and therapies, including vitamins, herbs, and supplements that you may be taking.
* You will be asked to describe any changes in your health or how you feel.
* You will have a neurological exam.
* Your vital signs will be measured.
* You will be asked to provide a blood sample (about 1 teaspoon), a urine sample and a swab of your nose and throat will be taken.
* You will have a blood test (about 4 teaspoons) to evaluate your clinical status.
* Blood (about 2 teaspoons) will be collected to look for the presence of anti-AD5 and virus.
* Women who are able to become pregnant must have a blood (about 1 teaspoon) pregnancy test on Day 13, 1 and 4 month visits and all follow-up visits after that.
* You will have an MRI on Days 7 and 13 only.

If you are feeling well 14 days after the first injection of study drug, you will be brought back to the operating room for a second procedure to remove the tumor. You will undergo a craniotomy, in which the skull over the tumor is removed to get to the brain and tumor. The neurosurgeon will try to remove the tumor as completely as possible with the catheter tip from the first procedure in place. After the tumor has been removed, you will receive another dose of DNX-2401 that will be injected into the brain tissue that surrounded the tumor to try to kill any remaining tumor cells. This is called "Stage 2." The skull will then be replaced and the skin closed. Within 6 hours of the craniotomy on Day 14, you will have a neurological exam and your vital signs will be measured.

On the day of resection, a sample of the removed brain tumor tissue will be collected and stored until the study is over. Analysis of the tissue will be performed to look for the presence and activity of the virus, as well as any additional tests that are necessary for protocol purposes.

Group B Follow-up Visits after Craniotomy:

After the surgery, you will be seen in the hospital or come back to the center on Days 15, 18, 21, 28, and 42, at 2, 3 and 4 months, and then every 2 months for 2 years. After that, you will be asked to come back every 4 months for the rest of your life. At each visit, the following tests and procedures will be performed:

* You will be asked to give information about any new medications and therapies, including vitamins, herbs, and supplements that you may be taking.
* You will be asked to describe any changes in your health or how you feel.
* You will have a neurological exam.
* Your weight will be measured on Day 28, 42 and at 2, 3 and 4 months only.
* Your vital signs will be measured.
* You will be asked to provide a blood sample (about 1 teaspoon), a urine sample, and a swab of your nose and throat.
* You will have a blood test (about 4 teaspoons) to evaluate your clinical status.
* Blood (about 2 teaspoons) will be drawn to look for the presence of anti-AD5 and virus.
* Women who can become pregnant must have a blood (about 1 teaspoon) pregnancy test at all visits except Day 15 and 18.
* You will have an MRI.

For participants who are clinically unable to wait 14 days for surgery because of the tumor's size and/or location, or because they are experiencing serious neurological symptoms, the study chair may decide to skip the biopsy.

Group B Follow-up Visits (Stage 2--Craniotomy Only):

After the surgery, you will be seen in the hospital or come back to the center on Days 1, 4, 7, 14, and 28; at 2, 3, and 4 months; and then every 2 months for 2 years. After that, you will be asked to come back every 4 months for the rest of your life. At each visit, the following tests and procedures will be performed:

* You will be asked to give information about any new medications and therapies, including vitamins, herbs, and supplements that you may be taking.
* You will be asked to describe any changes in your health or how you feel.
* You will have a neurological exam.
* Your weight will be measured on Day 28 and at 2, 3, and 4 months.
* Your vital signs will be measured.
* You will be asked to provide a blood sample (about 1 teaspoon), a urine sample, and a swab of your nose and throat.
* You will have a blood test (about 4 teaspoons) to evaluate your clinical status.
* Blood (about 2 teaspoons) will be drawn to look for the presence of anti-AD5 and virus.
* Women who can become pregnant must have a blood (about 1 teaspoon) pregnancy test on 1- and 4-month visit and all follow-up visits after that.
* You will have an MRI.

This is an investigational study. At this time, DNX-2401 is only being used in research. Up to 96 patients will take part in this study (up to 48 in Group A and 48 in Group B). All will be enrolled at MD Anderson.

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Each cohort of three subjects each sequentially assigned to escalating doses of DNX-2401, with acceptable grade of neurotoxicity Common Toxicity Criteria (CTC) \< grade 3, related to the study drug, and according to standard Gehan phase I dose-escalating criteria for toxicity.

DNAtrix, Inc.

Cicatrix

Colonic Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Colonic Diseases

Intestinal Diseases

Herbal and Botanical

Cola

Patients randomized to surgery are treated according to current guidelines with either open, laparoscopic or robotic surgical segmental bowel resection corresponding to lymphovascular drainage of the cancer.

Patients randomised to EFTR are treated using devices approved for eFTR in the European Union and affiliated countries for the indication as applied in the trial. Before EFTR, the scar is identified and documented. The colonoscope is then removed, the EFTR device mounted, the colonoscope re-introduced, and eFTR performed.

Removal of incompletely removed early-stage colon cancer

Tumor removal

Nastazja Pilonis, MD PhD

Michael Bretthauer, MD PhD

Jens Aksel Nielsen, MD

Linn Bernklev, MD

Michal Kaminski, MD PhD

Randomized head-to-head comparison trial among patients who have undergone incomplete endoscopic resection of early colon cancer to evaluate the benefits, harms and burdens, as well as the ecological footprint and cost-effectiveness of endoscopic full thickness resection (eFTR), a minimally invasive endoscopic treatment with a colonoscope, as compared to standard-of-care surgery.

Co-primary endpoints are

* Rate of severe adverse events classified as grade III to V according to the Clavien Dindo classification within 30-days after study treatment
* CRC recurrence or sign of lymph nodes or distant metastases at 3 years after randomization comparing the two treatment groups (eFTR versus surgery).

Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR

Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR (SCAR)- a Randomized Controlled Trial

Costs in dollars as compared to effectiveness

Rate of severe adverse events classified as grade III to V according to the Clavien Dindo classification within 30-days after study treatment

Rate of CRC recurrence or sign of lymph nodes or distant metastases

Carbon dioxide emission in kgCo2 per procedure

European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (0-100 points; higher point scores mean higher QoL)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S	NCT04430842	Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C...	QBS10072S	18 Years -	Quadriga Biosciences, Inc.
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas	NCT00805376	Brain Cancer Central Nervous...	DNX-2401 Tumor Removal	18 Years -	DNAtrix, Inc.
Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR	NCT06057350	Treatment Side ... Colorectal Canc...	Tumor removal	40 Years -	Norwegian Department of Health and Social Affairs

Spots Global Cancer Trial Database for tumor removal